PerkinElmer, Inc. (PKI) Insider Andrew Okun Sells 12,680 Shares

PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 12,680 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $72.00, for a total value of $912,960.00. Following the completion of the transaction, the insider now owns 25,121 shares of the company’s stock, valued at approximately $1,808,712. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of PerkinElmer, Inc. (NYSE:PKI) traded up $1.30 on Monday, hitting $72.13. The stock had a trading volume of 1,165,400 shares, compared to its average volume of 634,531. The company has a market cap of $7,950.53, a P/E ratio of 25.95, a PEG ratio of 2.16 and a beta of 0.77. The company has a current ratio of 2.59, a quick ratio of 2.09 and a debt-to-equity ratio of 0.44. PerkinElmer, Inc. has a 12-month low of $50.59 and a 12-month high of $74.11.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio (DPR) is presently 7.78%.

Several research analysts have commented on the company. Citigroup restated a “buy” rating and issued a $80.00 target price (up previously from $74.00) on shares of PerkinElmer in a research note on Tuesday, September 26th. ValuEngine downgraded PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen restated a “hold” rating and issued a $70.00 target price on shares of PerkinElmer in a research note on Friday, September 1st. Robert W. Baird restated a “buy” rating and issued a $72.00 target price on shares of PerkinElmer in a research note on Friday, October 20th. Finally, Morgan Stanley restated an “overweight” rating and issued a $77.00 target price (down previously from $79.00) on shares of PerkinElmer in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company’s stock. PerkinElmer has an average rating of “Hold” and a consensus target price of $68.64.

Several institutional investors and hedge funds have recently modified their holdings of PKI. Acrospire Investment Management LLC boosted its position in shares of PerkinElmer by 185.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 1,300 shares during the last quarter. Waldron LP purchased a new position in shares of PerkinElmer during the 3rd quarter valued at about $200,000. Seaward Management Limited Partnership purchased a new position in shares of PerkinElmer during the 3rd quarter valued at about $202,000. Carret Asset Management LLC purchased a new position in shares of PerkinElmer during the 2nd quarter valued at about $210,000. Finally, Cipher Capital LP purchased a new position in shares of PerkinElmer during the 2nd quarter valued at about $230,000. Hedge funds and other institutional investors own 91.66% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “PerkinElmer, Inc. (PKI) Insider Andrew Okun Sells 12,680 Shares” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/18/perkinelmer-inc-pki-insider-andrew-okun-sells-12680-shares.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit